Please use this identifier to cite or link to this item:
Title: Integration of antiangiogenic therapy with cisplatin and gemcitabine chemotherapy in patients with nasopharyngeal carcinoma.
Authors: Chong, Wan Qin
Lim, Chwee Ming 
Sinha, Arvind Kumar 
Tan, Chee Seng 
Chan, Gloria Hui Jia
Huang, Yiqing
Barr Kumarakulasinghe, Nesaretnam
Sundar, Raghav 
Jeyasekharan, Anand D 
Loh, Woei Shyang 
Tay, Joshua K. 
Yadav, Kritika 
Wang, Lingzhi 
Wong, Andrea L. 
Kong, Li Ren 
Soo, Ross Andrew 
Lau, Jieying Amelia 
Soon, Yu Yang 
Goh, Robby Miguel
Ho, Francis Cho Hao 
Chong, Siew Meng 
Lee, Soo-Chin 
Loh, Kwok Seng 
Tai, Bee Choo 
Lim, Yaw Chyn 
Goh, Boon Cher 
Issue Date: 14-Aug-2020
Publisher: American Association for Cancer Research (AACR)
Citation: Chong, Wan Qin, Lim, Chwee Ming, Sinha, Arvind Kumar, Tan, Chee Seng, Chan, Gloria Hui Jia, Huang, Yiqing, Barr Kumarakulasinghe, Nesaretnam, Sundar, Raghav, Jeyasekharan, Anand D, Loh, Woei Shyang, Tay, Joshua K., Yadav, Kritika, Wang, Lingzhi, Wong, Andrea L., Kong, Li Ren, Soo, Ross Andrew, Lau, Jieying Amelia, Soon, Yu Yang, Goh, Robby Miguel, Ho, Francis Cho Hao, Chong, Siew Meng, Lee, Soo-Chin, Loh, Kwok Seng, Tai, Bee Choo, Lim, Yaw Chyn, Goh, Boon Cher (2020-08-14). Integration of antiangiogenic therapy with cisplatin and gemcitabine chemotherapy in patients with nasopharyngeal carcinoma.. Clin Cancer Res : clincanres.1727.2020-clincanres.1727.2020. ScholarBank@NUS Repository.
Abstract: PURPOSE: Induction cisplatin and gemcitabine chemotherapy is a standard treatment for locally advanced NPC. Inhibition of VEGF axis has been shown to promote maturation of microvasculature and improve perfusion. We conducted a four-arm study to assess the effect of 2 doses of either sunitinib or bevacizumab with chemotherapy in NPC. EXPERIMENTAL DESIGN: Patients with treatment naïve locally advanced NPC were treated with 3 cycles of 3-weekly cisplatin and gemcitabine preceded by 1 week of anti-VEGF therapy for each cycle, followed by standard concurrent chemoradiation: Arm A patients received 7 days of 12.5mg/day sunitinib; Arm B 7 days of 25mg/day sunitinib; Arm C bevacizumab 7.5mg/kg infusion; Arm D bevacizumab 2.5mg/kg infusion. Patients with metastatic NPC were treated with up to 6 cycles of similar treatment without concurrent chemoradiation. RESULTS: Complete metabolic response (mCR) by whole body 18fluorodeoxyglucose PET was highest in Arm C (significant difference in 4 groups Fisher's exact test p=0.001; type 1 error=0.05), with 42% mCR (95% CI 18 - 67) and 3-year relapse free survival of 88% in patients with locally advanced NPC. Significant increase in pericyte coverage signifying microvascular maturation and increased immune cell infiltration was observed in post treatment tumor biopsies in Arm C. Myelosuppression was more profound in sunitinib containing arms, and tolerability was established in Arm C where hypertension was the most significant toxicity. CONCLUSION: Bevacizumab 7.5mg/kg with cisplatin and gemcitabine was well tolerated. Promising tumour response was observed and supported mechanistically by positive effects on tumour perfusion and immune cell trafficking into the tumour.
Source Title: Clin Cancer Res
ISSN: 10780432
DOI: 10.1158/1078-0432.CCR-20-1727
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Integration of antiangiogenic therapy with cisplatin and gemcitabine chemotherapy in patients with nasopharyngeal carcinoma..pdf1.9 MBAdobe PDF



Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.